- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 16.03. | Truist reiterates Rapport Therapeutics stock rating on phase 3 plans | 3 | Investing.com | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.03. | Rapport Therapeutics: Truist bestätigt Kaufempfehlung nach beschleunigten Phase-3-Plänen | 6 | Investing.com Deutsch | ||
| 11.03. | Stifel reiterates Rapport Therapeutics stock rating after results | 4 | Investing.com | ||
| 11.03. | Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress | 2 | Investing.com | ||
| 11.03. | BTIG raises Rapport Therapeutics stock price target on trial progress | 1 | Investing.com | ||
| 10.03. | Rapport Therapeutics GAAP EPS of -$0.72 misses by $0.03 | 1 | Seeking Alpha | ||
| 10.03. | Rapport Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 418 | GlobeNewswire (Europe) | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen | |
| 10.03. | Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential | 1 | Investing.com | ||
| 10.03. | Citizens bekräftigt Rating für Rapport Therapeutics wegen Potenzial bei Epilepsie-Wirkstoff | 1 | Investing.com Deutsch | ||
| 09.03. | BTIG reiterates Rapport Therapeutics stock rating citing selectivity | 2 | Investing.com | ||
| 09.03. | Rapport Therapeutics: China-Deal stützt Kaufempfehlung von TD Cowen | 3 | Investing.com Deutsch | ||
| 09.03. | Rapport Therapeutics stock holds Buy at TD Cowen on China deal | 1 | Investing.com | ||
| 09.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China | 326 | GlobeNewswire (Europe) | Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights... ► Artikel lesen | |
| 08.01. | Citizens reiterates Market Outperform rating on Rapport Therapeutics stock | 3 | Investing.com | ||
| 07.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | 806 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| 07.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 30,000 | +0,67 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,074 | +0,85 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| IMMUNITYBIO | 6,180 | -0,32 % | ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum | ||
| MICROBOT MEDICAL | 2,050 | +2,50 % | Microbot Medical announces full US launch of endovascular robot | ||
| ATAIBECKLEY | 3,220 | 0,00 % | Depression und PTBS im Fokus: Wie Emyria und AtaiBeckley neue Wirtschaftsmodelle in der Psychiatrie prägen | ||
| CYTOKINETICS | 56,18 | -0,92 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,097 | -1,88 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,216 | -1,17 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,465 | 0,00 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| CAPRICOR | 29,500 | +0,51 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| BIOAGE LABS | 13,350 | -2,98 % | BioAge Labs, Inc.: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,100 | -1,94 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,104 | -4,89 % | Abeona Therapeutics beruft Keith Goldan in den Verwaltungsrat | ||
| KALVISTA PHARMACEUTICALS | 16,170 | -2,82 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,300 | -2,11 % | Vir Biotechnology startet Erweiterungsstudie für Prostatakrebs-Wirkstoff VIR-5500 |
RAPPORT THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 34,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.